Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06082960 | Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors | PHASE1 | ACTIVE NOT_RECRUITING | 45 | — | — | Oct 9, 2023 | Dec 1, 2026 | Apr 16, 2026 | 6 | United States, Australia +1 |
| Arm | Type | Description |
|---|---|---|
| Part A: GS-9911 Monotherapy Dose Escalation | EXPERIMENTAL | Participants will receive escalating doses of GS-9911 monotherapy. |
| Part B: GS-9911 Monotherapy Dose Expansion | EXPERIMENTAL | Participants will receive GS-9911 monotherapy at the recommended dose for expansion (RDE) determined in Part A. |
| Part C: Dose Escalation: GS-9911 + Anti-PD-1 Monoclonal Antibody | EXPERIMENTAL | Participants will receive escalating doses of GS-9911 in combination with an anti-PD-1 monoclonal antibody (zimberelimab). |
| Part D: Dose Expansion: GS-9911 + Anti-PD-1 Monoclonal Antibody | EXPERIMENTAL | Participants will receive GS-9911 at RDE determined in Part C in combination with an anti-PD-1 monoclonal antibody (zimberelimab). |
| Name | Type | Description |
|---|---|---|
| GS-9911 | DRUG | Tablets administered orally |
| Zimberelimab | DRUG | Administered intravenously |
Key Inclusion Criteria: * Parts A, C, and D: * Participants with histologically or cytologically confirmed advanced solid tumors who have received, been intolerant to, or are ineligible for all treatments known to confer clinical benefit * Part B: * Participants whose cancer previously derive...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab, V503, GARDASIL |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| AstraZeneca PLC | AZN | 1 | — | Trastuzumab deruxtecan |